The FDA has approved Miudella, a hormone-free copper IUD, for pregnancy prevention for up to three years, marking the first approval of a new copper IUD in the U.S. in over 40 years.
"These differences were largely driven by the high rate of adverse events leading to study discontinuation in the OIT-treated participants, despite receiving omalizumab treatment at the initiation of therapy."
Dolutegravir led to faster virologic suppression and lower virologic failure rates than standard care, according to the ODYSSEY trial's latest analysis.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.